Drug intelligence / Profile preview

zaizao wan

Development stage: Unknown
Lead developer: Liaoning Jindan Pharmaceutical
Administration: Oral

Overview

Zaizao Wan is a traditional Chinese medicine (TCM) product manufactured by Liaoning Jindan Pharmaceutical. It is an approved pharmaceutical product in China, primarily indicated for the treatment of sequelae of stroke, including hemiplegia, facial paralysis, and numbness of limbs, as well as rheumatic conditions and joint pain. The formula is a complex mixture of over 50 ingredients, including herbs like Ginseng and various minerals and animal products, which work synergistically to dispel wind, resolve phlegm, promote blood circulation, and dredge meridians. It is typically administered orally in the form of large honey pills.

Brand names: Jindan
Other names: 再造丸Zaizao Pills

Targets

PRKCA (Protein kinase C alpha)PKA (Cyclic amp-dependent protein kinase)CREB (Cyclic AMP response element-binding protein)IKBKB (IKKβ)

Beyond the preview

Go deeper on zaizao wan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on zaizao wan.

Explore the full profile